KeyCorp Estimates Exagen’s FY2026 Earnings (NASDAQ:XGN)

Exagen Inc. (NASDAQ:XGN – Free Report) – KeyCorp issued their FY2026 earnings per share estimates for shares of Exagen in a report released on Tuesday, November 10th. KeyCorp analyst P. Knight expects that the company will post earnings per share of ($0.71) for the year. The consensus estimate for Exagen’s current full-year earnings is ($0.71) per share. KeyCorp also issued estimates for Exagen’s Q4 2026 earnings at ($0.16) EPS and FY2027 earnings at ($0.49) EPS.

A number of other analysts have also commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Exagen in a research note on Wednesday, November 4th. Wall Street Zen downgraded shares of Exagen from a “hold” rating to a “sell” rating in a research report on Saturday. Canaccord Genuity Group lowered their price target on Exagen from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Wednesday, November 11th. BTIG Research reissued a “buy” rating and set a $9.00 price target on shares of Exagen in a report on Wednesday, November 11th. Finally, TD Cowen raised their price target on Exagen from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $9.88.

Check Out Our Latest Stock Report on XGN

Exagen Stock Performance

Shares of NASDAQ XGN opened at $4.13 on Monday. The firm’s 50-day moving average price is $7.71 and its 200-day moving average price is $5.13. The company has a quick ratio of 3.46, a current ratio of 3.46 and a debt-to-equity ratio of 1.73. The company has a market cap of $105.36 million, a PE ratio of -5.51 and a beta of 2.25. Exagen has a 52-week low of $2.59 and a 52-week high of $9.28.

Exagen (NASDAQ:XGN – Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). The business had revenue of $18.42 million during the quarter, compared to analysts’ expectations of $18.34 million. Exagen had a negative return on equity of 125.60% and a negative net margin of 25.14%.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Flputnam Investment Management Co. boosted its holdings in shares of Exagen by 3.8% during the 3rd quarter. Flputnam Investment Management Co. now owns 299,828 shares of the company’s stock valued at $2,438,000 after purchasing an additional 11,018 shares during the last quarter. Corient Private Wealth LP purchased a new position in shares of Exagen during the second quarter valued at about $52,000. Penbrook Management LLC bought a new stake in shares of Exagen in the third quarter worth about $92,000. Calamos Advisors LLC bought a new stake in shares of Exagen in the third quarter worth about $94,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Exagen in the second quarter worth about $97,000. 75.25% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, major shareholder Jorey Chernett sold 109,436 shares of the stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $4.65, for a total value of $508,877.40. Following the completion of the sale, the insider directly owned 2,587,504 shares of the company’s stock, valued at $12,031,893.60. This represents a 4.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO John Aballi sold 34,294 shares of the firm’s stock in a transaction on Friday, October 16th. The shares were sold at an average price of $7.87, for a total transaction of $269,893.78. Following the sale, the chief executive officer owned 805,540 shares in the company, valued at $6,339,599.80. The trade was a 4.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders purchased 100,900 shares of company stock worth $568,660 and sold 213,063 shares worth $1,084,856. Company insiders own 10.40% of the company’s stock.

Top Exagen Stories

Here are a few of the latest stories about XGN:

  • Positive Sentiment: Exagen’s earnings call highlighted business growth and expansion of its testing platform, which may support its longer-term prospects. Article: Exagen Earnings Call Highlights Growth and Platform Expansion
  • Neutral Sentiment: Major shareholder Jorey Chernett recently made purchases as well as sales. KeyCorp’s 2026 loss estimate matches consensus, offering little change to current expectations.
  • Negative Sentiment: Exagen’s latest quarterly loss per share was wider than analysts expected, even though revenue slightly beat estimates. Wall Street Zen downgraded the stock to Sell, while Canaccord lowered its price target from $11 to $9 but maintained a Buy rating. Article: Exagen Stock Rating Cut to Sell Article: Exagen Stock Gets Price Target Trim

About Exagen

(Get Free Report)

Exagen Inc. is a diagnostics company focused on testing for autoimmune and rheumatic diseases. It develops and provides blood tests intended to help physicians assess and monitor conditions such as systemic lupus erythematosus and other connective tissue diseases. The company’s AVISE test portfolio includes diagnostic and monitoring tests that use proprietary biomarkers to support clinical evaluation. Its offerings are designed to provide information that may help clinicians distinguish among autoimmune conditions and guide patient care.

Recommended Stories

Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.